EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.30
+0.45 (+3.29%)
As of 11:45AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close13.84
Open13.92
Bid14.24 x 800
Ask14.29 x 2200
Day's Range13.51 - 14.37
52 Week Range9.74 - 27.82
Volume541,918
Avg. Volume1,172,741
Market Cap1.445B
Beta (5Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-2.04
Earnings DateAug 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.44
  • Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference
    Business Wire

    Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference

    Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights and will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details of both events are as follows:

  • Were Hedge Funds Right About Epizyme Inc (EPZM)?
    Insider Monkey

    Were Hedge Funds Right About Epizyme Inc (EPZM)?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares
    Simply Wall St.

    Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares

    Those following along with Epizyme, Inc. (NASDAQ:EPZM) will no doubt be intrigued by the recent purchase of shares by...

  • Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma
    Zacks

    Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma

    The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.

  • MarketWatch

    Epizyme's shares fall after receiving new FDA approval for cancer drug

    Shares of Epizyme Inc. were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or refractory follicular lymphoma. Tazverik was first approved by the FDA in January, to treat epithelioid sarcoma. "In our view, there remains no clear standard of care in the relapsed and/or refractory FL population as not all patients benefit from today's available therapies," Dr. Shefali Agarwal, Epizyme's chief medical officer of Epizyme, said in a news release. The monthly list price is $15,500 for all approved indications, a spokesperson for the company said in an email. However, the labels for the two new indications are narrower than some analysts had expected. "We believe this label may disappoint some investors who had expected a broad, biomarker agnostic label in the 3L setting," SVB Leerink's Andrew Berens wrote in a note. Other analysts see a rosier future for the drug, with Wedbush analysts saying "we believe meaningful adoption will occur without the genetic test based on the drug's competitive clinical profile." Epizyme's stock has declined 16.8% since the start of the year. The S&P 500 is down 3.5.%.

  • Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Epizyme (EPZM) Stock?

    Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

  • Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma
    Business Wire

    Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma

    Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma

  • Hedge Funds Aren’t Done Buying Epizyme Inc (EPZM)
    Insider Monkey

    Hedge Funds Aren’t Done Buying Epizyme Inc (EPZM)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

  • 2 Top Cancer Treatment Stocks to Buy in June
    Motley Fool

    2 Top Cancer Treatment Stocks to Buy in June

    Investors with extra cash on the sidelines may be able to capture some exciting cancer stocks at attractive prices. One company received approval from the Food and Drug Administration (FDA) for its cancer drug and is expanding to other indications. Another offers a promising pipeline with a strong patent portfolio that is in the process of regulatory submission.

  • Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound?
    Zacks

    Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Thomson Reuters StreetEvents

    Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT

    Q1 2020 Epizyme Inc Earnings Call

  • Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions
    Zacks

    Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions

    Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program
    Business Wire

    Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program

    Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program

  • Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
    Zacks

    Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses

    Allogene (ALLO) reports no revenues for the first quarter of 2020.

  • Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss
    Zacks

    Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss

    Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.

  • Epizyme Inc (EPZM) Q1 2020 Earnings Call Transcript
    Motley Fool

    Epizyme Inc (EPZM) Q1 2020 Earnings Call Transcript

    On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; Dr. Shefali Agarwal, Chief Medical Officer; and Paolo Tombesi, Chief Financial Officer who will join us for the Q&A session. This approval made TAZVERIK the first and only FDA-approved treatment specifically indicated for epithelioid sarcoma patients and the first and only approved EZH2 inhibitor on the market.

  • Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates

    Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Epizyme: Q1 Earnings Insights

    Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.Quarterly Results Earnings per share fell 30.77% over the past year to ($0.51), which beat the estimate of ($0.74).Revenue of $1,354,000 less by 82.84% from the same period last year, which missed the estimate of $3,680,000.Guidance Epizyme hasn't issued any earnings guidance for the time being.Epizyme hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: May 04, 2020View more earnings on EPZMTime: 03:04 AM ETWebcast URL: https://edge.media-server.com/mmc/p/shejfym8Price Action Company's 52-week high was at $27.82Company's 52-week low was at $9.73Price action over last quarter: down 26.71%Company Profile Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.See more from Benzinga * Stocks That Hit 52-Week Lows On Friday * Price Over Earnings Overview: Michaels Companies * Morning Market Stats in 5 Minutes(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Epizyme Reports Business Progress and First Quarter 2020 Financial Results
    Business Wire

    Epizyme Reports Business Progress and First Quarter 2020 Financial Results

    Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2020 financial results.

  • Epizyme Announces Date of First Quarter 2020 Financial Results
    Business Wire

    Epizyme Announces Date of First Quarter 2020 Financial Results

    Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2020 financial results and other business highlights on Monday, May 4, 2020 at 9:00 a.m. ET.

  • Is Epizyme, Inc.'s (NASDAQ:EPZM) CEO Overpaid Relative To Its Peers?
    Simply Wall St.

    Is Epizyme, Inc.'s (NASDAQ:EPZM) CEO Overpaid Relative To Its Peers?

    Bob Bazemore became the CEO of Epizyme, Inc. (NASDAQ:EPZM) in 2015. This report will, first, examine the CEO...

  • Is Epizyme Inc (EPZM) A Good Stock To Buy?
    Insider Monkey

    Is Epizyme Inc (EPZM) A Good Stock To Buy?

    Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

  • Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
    Business Wire

    Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer

    Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer

  • Thomson Reuters StreetEvents

    Edited Transcript of EPZM earnings conference call or presentation 24-Feb-20 1:30pm GMT

    Q4 2019 Epizyme Inc Earnings Call

  • Epizyme, Inc. Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
    Simply Wall St.

    Epizyme, Inc. Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

    A week ago, Epizyme, Inc. (NASDAQ:EPZM) came out with a strong set of yearly numbers that could potentially lead to a...